Apogee Therapeutics (APGE) CFO sells 2,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson reported an open-market sale of 2,000 shares of common stock at $90.00 per share on April 16, 2026. Following this transaction, she directly holds 175,371 shares of Apogee common stock.

According to a footnote, this sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 2, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 2,000 shares ($180,000)

Net Sell 1 txn

Insider Henderson Jane

Role Chief Financial Officer

Sold 2,000 shs ($180K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,000	$90.00	$180K

Holdings After Transaction: Common Stock — 175,371 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 2,000 shares Sale price: $90.00 per share Transaction value: $180,000 +2 more

5 metrics

Shares sold 2,000 shares Open-market sale of common stock on April 16, 2026

Sale price $90.00 per share Price for the 2,000-share open-market transaction

Transaction value $180,000 2,000 shares sold at $90.00 per share

Shares held after sale 175,371 shares Direct ownership following the reported transaction

Sell transactions 1 transaction Form 4 transaction summary net-sell activity

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4, non-derivative

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

""transaction_type": "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Henderson Jane

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/16/2026		S(1)		2,000	D	$90	175,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.

	/s/ Matthew Batters, as attorney-in-fact for Jane Pritchett Henderson	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Apogee Therapeutics (APGE) disclose?

Apogee Therapeutics disclosed that CFO Jane Henderson sold 2,000 shares of common stock at $90.00 per share. The transaction was an open-market sale and was reported on Form 4 as a routine insider trading disclosure for investors.

How many Apogee Therapeutics (APGE) shares does the CFO still hold after the sale?

After the sale, CFO Jane Henderson directly holds 175,371 shares of Apogee common stock. This figure comes from the Form 4, which reports the insider’s remaining direct ownership position following the 2,000-share open-market transaction.

Was the Apogee Therapeutics (APGE) insider sale made under a Rule 10b5-1 plan?

Yes. A footnote states the transaction was executed under a Rule 10b5-1 trading plan adopted on September 2, 2025. Such plans pre-schedule trades, reducing the significance of trade timing as an indicator of the insider’s near-term outlook.

What price did the Apogee Therapeutics (APGE) CFO receive per share in the sale?

The CFO’s open-market sale was executed at $90.00 per share. With 2,000 shares sold, the gross transaction value totaled $180,000, as reported in the Form 4’s transaction details for the non-derivative common stock sale.

What type of security did the Apogee Therapeutics (APGE) insider sell?

The transaction involved non-derivative common stock of Apogee Therapeutics. The Form 4 specifies that 2,000 shares of common stock were sold in an open-market transaction, and there were no related derivative exercises or derivative holdings reported in this filing.